HK Stock Market Move | [01952] Everest Medical-B shares closed up nearly 4% at the end of trading. Institutions believe that the sales guidance for Nufucang is positive, and income is expected to grow rapidly after being insured.

Everest MED-B (01952) rose nearly 4% in the final hour of trading, rising 3.79% to HK$39.75, with a trading volume of HK$148 million as of press time. Citigroup released a research report stating that the bank recently held a meeting with Everest MED-B, where management guided sales of HK$1.4 billion by 2025, including HK$1 billion for Nafacorte and HK$400 million for Xerava. Nafacorte has successfully been included in the national medical insurance. The report highlighted key catalysts for the company this year including Nafacorte's sales performance, mRNA candidate FIH data in June and further data on EVER001 in September. China Great Wall mentioned that Nafacorte has smoothly entered the 2024 version of the medical insurance catalog, and the bank is optimistic about Nafacorte and its commercialization capabilities. With the gradual implementation of the new medical insurance catalog and local procurement schemes, Nafacorte's revenue is expected to grow rapidly, with projected revenues of HK$400 million, HK$1.2 billion, and HK$1.8 billion from 2024 to 2026. The bank also stated that EVER001 has the potential to become the leading product in its category for treating primary membranous nephropathy.